Search results for "Platelet"

showing 10 items of 786 documents

Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH…

2018

During the last few years, the number of patients receiving anticoagulant and antiplatelet therapy has increased worldwide. Since this is a chronic treatment, patients receiving it can be expected to need some kind of surgery or intervention during their lifetime that may require treatment discontinuation. The decision to withdraw antithrombotic therapy depends on the patient's thrombotic risk versus hemorrhagic risk. Assessment of both factors will show the precise management of anticoagulant and antiplatelet therapy in these scenarios. The aim of this consensus document, coordinated by the Cardiovascular Thrombosis Working Group of the Spanish Society of Cardiology, and endorsed by most o…

Malemedicine.medical_specialtymedicine.drug_classHemorrhage030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRisk FactorsThromboembolismIntervention (counseling)Preoperative CareAntithromboticmedicineHumans030212 general & internal medicineIntensive care medicineAgedAged 80 and overThrombotic riskIntraoperative CareDrug Substitutionbusiness.industryAnticoagulantAnticoagulantsGeneral MedicinePerioperativemedicine.diseaseThrombosisDiscontinuationConventional PCIFemaleAntiagregación Anticoagulación Anticoagulation Antiplatelet Antithrombotic Antitrombótico Cirugía SurgerybusinessPlatelet Aggregation InhibitorsRevista Española de Cardiología (English Edition)
researchProduct

Anticoagulation prescription in atrial fibrillation.

2011

We seek to assess the factors associated with the anticoagulation prescription in a cohort of patients with atrial fibrillation (AF) collected from out-patient clinics.A total of 1524 patients with a history of AF were collected from out-patients clinics. CHADS(2), CHA(2)DS(2)-VASc and HAS-BLED scores were calculated in every patient. Variables associated with anticoagulant treatment prescription were analyzed in univariant and multivariant models.Most patients received either anticoagulant (62%) or antiplatelet treatment (37%). Anticoagulation rates increased among higher CHADS(2) and CHA(2)DS(2)-VASc score values. A logistic regression model was performed to assess the variables associate…

Malemedicine.medical_specialtymedicine.drug_classHemorrhageLogistic regressionAmbulatory Care FacilitiesRisk FactorsInternal medicineAtrial FibrillationmedicineHumansPharmacology (medical)Medical prescriptionPractice Patterns Physicians'AgedPharmacologyAged 80 and overbusiness.industryAnticoagulantAnticoagulantsAtrial fibrillationThrombosisGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseLogistic ModelsAnticoagulant therapyConcomitantCohortMultivariate AnalysisCardiologyFemalebusinessPlatelet Aggregation InhibitorsExpert opinion on pharmacotherapy
researchProduct

Effects of endotoxin on neurally-mediated gastric acid secretion in the rat.

1998

Abstract The effects of a peripheral administration of E. coli endotoxin on neurally-mediated gastric acid secretion and the role of endogenous opioids or PAF receptors in endotoxin effects have been evaluated in the continuously perfused stomach of the anaesthetized rat. Gastric acid secretion stimulated by distension (20 cm H2O) was reduced dose-dependently by single intravenous bolus injection of endotoxin (0.1–10 μg kg−1). Doses of 5 μg kg−1 induced a peak reduction of distension-stimulated acid output and significantly reduced the secretory response induced by an intravenous bolus of 2-deoxy-d-glucose (150 mg kg−1). This dose of endotoxin did not significantly modify mean systemic arte…

Malemedicine.medical_specialtymedicine.drug_classNarcotic AntagonistsPharmaceutical ScienceBlood PressureReceptors Cell Surface(+)-NaloxonePlatelet Membrane GlycoproteinsDistensionDeoxyglucoseReceptors G-Protein-CoupledGastric AcidOpioid receptorInternal medicinemedicineEscherichia coliAnimalsRats WistarEndogenous opioidPharmacologyDose-Response Relationship Drugbusiness.industryNaloxoneGastric distensionStomachAntagonistAzepinesTriazolesReceptor antagonistRatsEndotoxinsEndocrinologyOpioid PeptidesReceptors OpioidGastric acidFemalemedicine.symptombusinessPlatelet Aggregation InhibitorsThe Journal of pharmacy and pharmacology
researchProduct

Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer

2016

Abstract Background The most common presenting symptom of bladder cancer (BCa) is hematuria. The present study was designed to define whether patients taking antiplatelet and/or anticoagulant drugs might experience hematuria at an earlier stage or grade of BCa. Patients and Methods The data from 1532 consecutive patients who presented to the emergency unit of our institute from 2004 to 2012 because of gross hematuria as a single symptom were evaluated. Patients (n = 227) with a further diagnosis of BCa were included in our study. For the purpose of the present study, patients were divided into 2 groups: patients receiving antiplatelet or anticoagulant therapy (AAT) (group 1) and patients no…

Malemedicine.medical_specialtymedicine.drug_classUrology030232 urology & nephrologyLogistic regressionSettore MED/24 - Urologia03 medical and health sciences0302 clinical medicineRetrospective StudieInternal medicinemedicineHumansAntiplateletStage (cooking)Macroscopic hematuriaAnticoagulant; Antiplatelet; Bladder cancer; Emergency room; Hematuria; Non-muscle invasive bladder cancerEarly Detection of CancerRetrospective StudiesHematuriaAgedNeoplasm StagingBladder cancerbusiness.industryPlatelet Aggregation InhibitorAnticoagulantBladder cancerAnticoagulantAnticoagulantsRetrospective cohort studyEmergency roomOdds ratioMiddle Agedmedicine.diseaseSurgeryUrinary Bladder NeoplasmsOncology030220 oncology & carcinogenesisUrinary Bladder NeoplasmPlatelet aggregation inhibitorFemalebusinessNon-muscle invasive bladder cancerPlatelet Aggregation InhibitorsHuman
researchProduct

CAPD + hemoperfusion once a week in the management of children with end-stage renal disease

1983

With hemoperfusion there is a sharp decline in the solute concentration of the blood compartment, but immediately after HP the concentration of these substances rises to the original level (post-Hp rebound). It may be inferred that the result would be better and the rebound phenomenon less marked if hemoperfusion could be combined with a continuous dialysis system such as CAPD. The study was performed in 3 children of our CAPD programm. All patients were dialysed with 5 daily exchange each of one liter. The patients underwent at 2-hours hemoperfusion with a charcoal column (Gambro Adsorba 150 c) once a week. The data obtained with this form of treatment are indicative for a: significant in…

Malemedicine.medical_specialtymedicine.medical_treatment030232 urology & nephrologyBiomedical EngineeringUrologyMedicine (miscellaneous)Bioengineering030204 cardiovascular system & hematologyEnd stage renal diseasePeritoneal dialysisBiomaterials03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePeritoneal Dialysis Continuous AmbulatoryHumansMedicinePlatelet activationChildIntensive care medicineDialysisCreatininebusiness.industryLiterGeneral MedicineHemoperfusionUric AcidHemoperfusionchemistryCreatinineKidney Failure ChronicUric acidFemalebusinessPeritoneal Dialysis
researchProduct

Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral …

2017

Abstract Background Patients with peripheral artery disease (PAD) undergoing a lower-extremity revascularization are at heightened risk for ischemic cardiac and limb events. Although intensification of antithrombotic therapy after revascularization has demonstrated benefit in coronary disease populations, this approach has not been well studied or shown consistent benefit in PAD. Recent trial evidence demonstrated that a treatment strategy of rivaroxaban added to background antiplatelet therapy reduced ischemic risk in patients following recent acute coronary syndromes, as well as in patients with stable atherosclerotic vascular disease. Whether these benefits extend to the population of pa…

Malemedicine.medical_specialtymedicine.medical_treatmentPopulation030204 cardiovascular system & hematologyRevascularizationlaw.invention03 medical and health sciencesPeripheral Arterial Disease0302 clinical medicineRandomized controlled trialDouble-Blind MethodRivaroxabanlawInternal medicinemedicineHumans030212 general & internal medicineMyocardial infarctioneducationRivaroxabaneducation.field_of_studyAspirinDose-Response Relationship Drugbusiness.industryEndovascular ProceduresThrombolysisMiddle Agedmedicine.diseaseClinical trialTreatment OutcomeLower ExtremityCardiologyPurinergic P2Y Receptor AntagonistsPlatelet aggregation inhibitorDrug Therapy CombinationFemaleCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugFactor Xa InhibitorsFollow-Up StudiesAmerican heart journal
researchProduct

Early and late mortality of spontaneous hemorrhagic transformation of ischemic stroke.

2014

Background Hemorrhagic transformation (HT), a complication of ischemic stroke (IS), might influence patient's prognosis. Our aim is to evaluate, in a hospital-based series of patients not treated with thrombolysis, the relationship between HT and mortality. Methods We compared mortality of individuals with spontaneous HT with that of individuals without. Medical records of patients diagnosed with anterior IS were retrospectively reviewed. Outcome measures were 30- and 90-day survival after IS onset. Kaplan–Meier estimates were used to construct survival curves. Cox proportional hazards model was used to estimate hazard ratio (HR) for the main outcome measure (death). HT was stratified in he…

Malemedicine.medical_specialtysurvivalBrain IschemiaCohort StudiesHematomaRisk FactorsInternal medicineMedicineHumansStrokeSurvival analysisAgedRetrospective StudiesAged 80 and overIschemic strokeAspirinbusiness.industryProportional hazards modelHeparinMortality rateRehabilitationHazard ratioAnticoagulantsIschemic stroke; epidemiology; hemorrhagic transformation; prognosis; survivalMiddle Agedmedicine.diseaseConfidence intervalSurgeryStrokeSurvival Ratehemorrhagic transformationCardiologyDisease ProgressionepidemiologySettore MED/26 - NeurologiaSurgeryFemaleNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessComplicationIntracranial HemorrhagesprognosiPlatelet Aggregation InhibitorsFollow-Up StudiesJournal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
researchProduct

Ischemic stroke risk during long-term follow up in patients with successful catheter ablation for atrial fibrillation in Korea

2018

The interruption of oral anticoagulation therapy (OAC) after CA of atrial fibrillation (AF) is controversial. The purpose of this study was to evaluate the relationship between successful long-term outcomes of catheter resection and SR maintenance and ischemic stroke risk in Korea. We studied 1,548 consecutive patients who were followed up for more than 2 years after CA of AF. We investigated the incidence of ischemic stroke during long-term follow-up. Compared to the AF recurrence group (n = 619), the sinus rhythm (SR) maintenance group (n = 929) had more paroxysmal AF (74.6% versus 44.4%, p<0.001), smaller LA size (39.9±5.7mm versus 42.3±6.0mm, p<0.001), and younger age (54.2±10.9 years v…

Malemedicine.medical_treatmentAnticoagulant Therapylcsh:Medicine030204 cardiovascular system & hematologyAntiplatelet TherapyPathology and Laboratory MedicineVascular MedicineBrain IschemiaGeographical LocationsElectrocardiography0302 clinical medicineRisk FactorsAtrial FibrillationMedicine and Health SciencesMedicineSinus rhythm030212 general & internal medicinelcsh:ScienceMultidisciplinaryPharmaceuticsIncidence (epidemiology)IncidenceAtrial fibrillationMiddle AgedStrokeCatheterCardiovascular TherapyBioassays and Physiological AnalysisNeurologyCardiologyCatheter AblationFemaleArrhythmiaResearch ArticleBiotechnologymedicine.medical_specialtyCathetersAsiaLong term follow upCerebrovascular DiseasesCardiologyCatheter ablationHemorrhageResearch and Analysis Methods03 medical and health sciencesSigns and SymptomsDrug TherapyDiagnostic MedicineInternal medicineRepublic of KoreaHumansIn patientIschemic StrokeKoreabusiness.industrylcsh:RElectrophysiological TechniquesBiology and Life Sciencesmedicine.diseaseIschemic strokePeople and Placeslcsh:QMedical Devices and EquipmentCardiac ElectrophysiologybusinessFollow-Up StudiesPLoS ONE
researchProduct

Splenic marginal zone lymphoma: A prognostic model for clinical use

2006

The Integruppo Italiano Linfomi (IIL) carried out a study to assess the outcomes of splenic marginal zone lymphoma and to identify prognostic factors in 309 patients. The 5-year cause-specific survival (CSS) rate was 76%. In univariate analysis, the parameters predictive of shorter CSS were hemoglobin levels below 12 g/dL (P < .001), albumin levels below 3.5 g/dL (P = .001), International Prognostic Index (IPI) scores of 2 to 3 (P < .001), lactate dehydrogenase (LDH) levels above normal (P < .001), age older than 60 years (P = .01), platelet counts below 100 000/μL (P = .04), HbsAg-positivity (P = .01), and no splenectomy at diagnosis (P = .006). Values that maintained a negative influence …

Malesplenic marginal zone lymphoma; prognostic factors; International Prognostic Index (IPI)VILLOUS LYMPHOCYTESHydro-LyaseB-CELLLongitudinal StudiePredictive Value of TestInternational Prognostic Index (IPI)BiochemistryGastroenterologyHemoglobinschemistry.chemical_compoundInternational Prognostic IndexRisk FactorsBONE-MARROW INFILTRATION; NON-HODGKINS-LYMPHOMA; C VIRUS-INFECTION; VILLOUS LYMPHOCYTES; B-CELLBONE-MARROW INFILTRATIONAge FactorLongitudinal StudiesMultivariate AnalysiAged 80 and overUnivariate analysisHematologyMortality rateAge FactorsHematologyMiddle AgedPrognosisSplenic NeoplasmSurvival RatePredictive value of testsHumanAdultmedicine.medical_specialtyLymphoma B-CellPrognosiImmunologysplenic marginal zone lymphomaDisease-Free SurvivalPredictive Value of TestsAlbuminsInternal medicineLactate dehydrogenaseAdult; Age Factors; Aged; Aged 80 and over; Albumins; Disease-Free Survival; Hemoglobins; Humans; Hydro-Lyases; Longitudinal Studies; Lymphoma B-Cell; Male; Middle Aged; Multivariate Analysis; Platelet Count; Predictive Value of Tests; Prognosis; Risk Factors; Splenic Neoplasms; Survival Rate; Models Theoretical; HematologymedicineHumansHemoglobinNON-HODGKINS-LYMPHOMASplenic marginal zone lymphomaSurvival rateHydro-LyasesAgedPlatelet Countbusiness.industrySplenic NeoplasmsAlbuminRisk Factorprognostic factorsCell BiologyModels Theoreticalmedicine.diseaseSurgerychemistryMultivariate AnalysisbusinessC VIRUS-INFECTION
researchProduct

Modification of human platelet adhesion on biomaterial surfaces by protein preadsorption under static and flow conditions.

2004

Biomaterial-induced thrombosis remains one of the main complications of vascular implant devices. Preadsorbed proteins on the biomaterial/blood interface will modify the adhesion and activation of platelets (PTLs) during the initial contact-phase. Our results clearly show that PTL-adherence on biomaterials is influenced not only by protein preadsorption, but also by flow conditions. The covalent coating of TCPS and glass by phosphorylcholine (PC) induces a significant decrease of PTL adhesion but leads to a slight, but nevertheless significant activation of PTL, which was detected by the induction of P-selectin expression using FACS analysis. Methodologically, the visualization of PTL adhes…

Materials scienceBiomedical EngineeringBiophysicschemistry.chemical_elementBioengineeringBiocompatible MaterialsCalciumIn Vitro TechniquesBiomaterialsBlood cellPlatelet AdhesivenessIn vivoMaterials TestingmedicineHumansPlateletPhosphorylcholineBiomaterialThrombosisAdhesionBlood ProteinsFlow CytometryPlatelet ActivationBiomechanical PhenomenaBlood Vessel ProsthesisP-Selectinmedicine.anatomical_structurechemistryembryonic structuresImmunologyHemorheologyBiophysicsAdsorptionProtein adsorptionJournal of materials science. Materials in medicine
researchProduct